Full Press Release Details
BridgeBio Pharma Announces Acoramidis Phase 3 ATTRibute-CM Data Presented At AHA And Published In NEJM.
BBIO
BridgeBio Pharma Announces Acoramidis Phase 3 ATTRibute-CM Data Presented At AHA And Published In NEJM
Key Takeaway: BridgeBio Pharma Announces Acoramidis Phase 3 ATTRibute-CM Data Presented At AHA And Published In NEJM
Price reaction · baseline $27.1 (2023-11-10 close) · clean, no other BBIO news in the window
day 0 close · peak
+1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis